This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Epigenetics: New Mechanisms, New Therapies (B4)


Organizer(s) Fran├žois Fuks and Anne Brunet
February 10—14, 2018
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Oct 10, 2017
Abstract Deadline: Nov 8, 2017
Scholarship Deadline: Oct 10, 2017
Discounted Registration Deadline: Dec 12, 2017

Sponsored by Cancer Research UK, Cell Research, Incyte Corporation, Merck & Co., Inc., Novartis Institutes for BioMedical Research, Pfizer Inc. and Roche

Summary of Meeting:
The field of epigenetics has recently emerged as an essential component of oncology research, with altered epigenetic modifications considered to be critical hallmarks of cancers. Unlike mutations, epigenetic aberrations are reversible and as a result, epigenetic therapies hold great promise as anti-cancer agents. For these novel therapies to succeed, a key challenge is to fully understand the nature and the mechanisms that lead to epigenetic changes in cancer. Another essential challenge is to make sense of the avalanche of data flowing from increasingly powerful "omics-based" technologies. Despite these challenges, never has the potential for scientific and clinical breakthroughs in this field been greater. Bringing together both the academic and the pharmaceutical communities, this Keystone Symposia conference will focus on: 1) The newest findings concerning the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells, and how these go awry during aging and cancer, with a special emphasis on histone modifications, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine); 2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics; 3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications; and 4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the burgeoning area of cancer epigenetics.

View Meeting Program

Scholarships/Awards

Keystone Symposia Future of Science Fund Scholarship Recipients

David I. Remillard
Harvard University, USA

Sandra Schick
CeMM GmbH, Austria

National Cancer Institute (NCI) Scholarship Recipients

Elizabeth J. Adams
Memorial Sloan Kettering Cancer Center, USA

Eduardo Torre
University of Pennsylvania, USA

Wenbing Xie
Johns Hopkins School of Medicine, USA